These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 37425042)

  • 1. Targeting histone deacetylases for cancer therapy: Trends and challenges.
    Liang T; Wang F; Elhassan RM; Cheng Y; Tang X; Chen W; Fang H; Hou X
    Acta Pharm Sin B; 2023 Jun; 13(6):2425-2463. PubMed ID: 37425042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current trends in development of HDAC-based chemotherapeutics.
    Cheshmazar N; Hamzeh-Mivehroud M; Nozad Charoudeh H; Hemmati S; Melesina J; Dastmalchi S
    Life Sci; 2022 Nov; 308():120946. PubMed ID: 36096240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
    Ganai SA
    Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer's disease.
    Li Y; Lin S; Gu Z; Chen L; He B
    Bioorg Med Chem Lett; 2022 Nov; 76():129015. PubMed ID: 36208870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.
    Jenke R; Reßing N; Hansen FK; Aigner A; Büch T
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities.
    Rodrigues DA; Pinheiro PSM; Sagrillo FS; Bolognesi ML; Fraga CAM
    Med Res Rev; 2020 Nov; 40(6):2177-2211. PubMed ID: 32588916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylases as targets in autoimmune and autoinflammatory diseases.
    Hamminger P; Rica R; Ellmeier W
    Adv Immunol; 2020; 147():1-59. PubMed ID: 32981634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing class I histone deacetylases (HDAC) with proteolysis targeting chimera (PROTAC) for the development of highly potent and selective degraders.
    Ibrahim HS; Guo M; Hilscher S; Erdmann F; Schmidt M; Schutkowski M; Sheng C; Sippl W
    Bioorg Chem; 2024 Oct; 153():107887. PubMed ID: 39423771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention.
    Ruzic D; Djoković N; Srdić-Rajić T; Echeverria C; Nikolic K; Santibanez JF
    Pharmaceutics; 2022 Jan; 14(1):. PubMed ID: 35057104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
    Uba AI; Yelekçi K
    J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current HDAC Inhibitors in Clinical Trials.
    Di Bello E; Noce B; Fioravanti R; Mai A
    Chimia (Aarau); 2022 May; 76(5):448-453. PubMed ID: 38069716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
    Peng X; Sun Z; Kuang P; Chen J
    Eur J Med Chem; 2020 Dec; 208():112831. PubMed ID: 32961382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of PROTAC in HDAC.
    Chen S; Zheng Y; Liang B; Yin Y; Yao J; Wang Q; Liu Y; Neamati N
    Eur J Med Chem; 2023 Nov; 260():115746. PubMed ID: 37607440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
    Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
    Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
    Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
    PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational Design and Development of HDAC Inhibitors for Breast Cancer Treatment.
    Mody D; Bouckaert J; Savvides SN; Gupta V
    Curr Pharm Des; 2021; 27(45):4610-4629. PubMed ID: 34533439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.
    Xu X; Xie C; Edwards H; Zhou H; Buck SA; Ge Y
    PLoS One; 2011 Feb; 6(2):e17138. PubMed ID: 21359182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor based prodrugs.
    Fan W; Zhang L; Jiang Q; Song W; Yan F; Zhang L
    Eur J Med Chem; 2020 Oct; 203():112628. PubMed ID: 32679451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy.
    Zhang L; Han Y; Jiang Q; Wang C; Chen X; Li X; Xu F; Jiang Y; Wang Q; Xu W
    Med Res Rev; 2015 Jan; 35(1):63-84. PubMed ID: 24782318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.